Generic Name and Formulations:
Ofloxacin 0.3%; oph. soln; contains benzalkonium chloride.
Indications for OCUFLOX:
Susceptible infections of the conjuctiva and corneal ulcer.
Adults and Children:
<1yr: not established. ≥1yr: Conjunctivitis: 1–2 drops every 2–4hrs for 2 days, then 4 times daily for 5 more days. Corneal ulcer: 1–2 drops every 30mins while awake and at 4hrs & 6hrs after retiring for sleep for 2 days, then 1–2 drops every 1hr while awake for days 3 through 7–9, then 1–2 drops 4 times daily through treatment completion.
Discontinue if superinfection or hypersensitivity occurs. Pregnancy. Nursing mothers: not recommended.
Possible potentiation of theophylline, caffeine, oral anticoagulants, cyclosporine if systemic absorption occurs.
Ocular burning/discomfort, redness, itching, chemical conjunctivitis/keratitis, ocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, eye pain.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Predictors of Weight Loss in Postpartum Women With Gestational Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D